NCT07194317

Brief Summary

New medications that work on gut hormones such as semaglutide (Wegovy) and tirzepatide (Mounjaro) are helping many people lose weight and are now recommended for treating obesity by the NHS. While these treatments are effective for weight loss, we don't yet know how they affect what people eat or their overall nutrition. Understanding diet before, during, and after treatment is important. Traditional ways of tracking diet, like paper food diaries, can be difficult to use and are time consuming for clinicians to interpret and record in clinical notes. Digital tools like MyFood24, Nutritics-Libro, and Intake24 may offer a better way to record what people eat, but we need to find out if they can be easily used in everyday healthcare settings. The FIDGET study will test how well these digital diet tools can be used in clinics and linked with electronic health records. The study will use surveys and group discussions to understand how patients and healthcare professionals feel about using these tools.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2025

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

September 8, 2025

Completed
18 days until next milestone

First Posted

Study publicly available on registry

September 26, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
Last Updated

September 26, 2025

Status Verified

September 1, 2025

Enrollment Period

6 months

First QC Date

September 8, 2025

Last Update Submit

September 18, 2025

Conditions

Keywords

Digital healthDiet AssessmentAcceptability testing

Outcome Measures

Primary Outcomes (2)

  • Usability

    Participants will complete a questionnaire to assess their experience and acceptability of using the tool. The System Usability Scale (SUS) will be used to measure the usability of the digital dietary assessment tools. A higher score denotes the system is more user friendly.

    Following each test period of 1 week

  • Usability and context of use

    Participants will complete a questionnaire to assess their experience and acceptability of using the tool. The modified version of the Rawl Usability Questionnaire - this measures the usability of specific features of digital applications and context of use.

    Following each test period of 1 week]

Secondary Outcomes (1)

  • Patient experience and acceptability

    Within 4 months of completion of the tool testing

Study Arms (1)

Feasibility and acceptability

OTHER

Participants will record their dietary intake over three weeks, using a different tool for three consecutive days each week. The digital tools are: MyFood24, Nutritics-Libro and Intake24.The order sequence to complete will be from auto number generation.

Device: Testing 3 different digital dietary assessment tools in a random order (Nutritics-Libro, MyFood24 and Intake24)

Interventions

55 participants will be recruited (target to complete the study n=50). The acceptability trial will be conducted remotely. A baseline questionnaire will capture demographic data. Over three weeks participants will be asked to record three random consecutive days of dietary intake each week using a different tool. Participants will be randomised to the order they complete the tools. To minimise potential biases. Participants will be randomly assigned to one of the six possible tool completion sequences (Table 1) using a relevant participant randomization package (e.g., rempsyc) in R (v4.4.2), which is a free, open-source statistical software used for data analysis and randomisation.

Feasibility and acceptability

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged \>18 years
  • Living with obesity as diagnosed by healthcare professional.
  • Referral to T3WMS at GSTT and currently on the service waiting list
  • Eligible for GLP-1 receptor agonist (Wegovy) prescription
  • Have an active MyChart account
  • Have an email address
  • Access to a digital device such as a smart phone, computer or tablet where you can access the internet
  • Not following a meal replacement diet, for example soups / shakes
  • Able to provide informed consent.
  • Able to complete surveys in English.

You may not qualify if:

  • Adults aged \>18 years
  • Living with obesity as diagnosed by healthcare professional.
  • Referral to T3WMS at GSTT and currently on the service waiting list
  • Eligible for GLP-1 receptor agonist (Wegovy) prescription
  • Have an active MyChart account
  • Have an email address
  • Access to a digital device such as a smart phone, computer or tablet where you can access the internet
  • Not following a meal replacement diet, for example soups / shakes
  • Able to provide informed consent.
  • Able to complete surveys in English.
  • Not able to provide informed consent
  • Not able to complete surveys in English
  • Has an eating disorder
  • Taking part in another research trial that involves dietary modification

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guy's and St Thomas' NHS Trust

London, Southwark, SE1 9NH, United Kingdom

Location

Related Publications (4)

  • Tanihara M, Suzuki Y, Yamamoto E, Noguchi A, Mizushima Y. Sustained release of basic fibroblast growth factor and angiogenesis in a novel covalently crosslinked gel of heparin and alginate. J Biomed Mater Res. 2001 Aug;56(2):216-21. doi: 10.1002/1097-4636(200108)56:23.0.co;2-n.

    PMID: 11340591BACKGROUND
  • Polack FM. Modification of the immune graft response by azathioprine. Surv Ophthalmol. 1966 Aug;11(4):545-53. No abstract available.

    PMID: 5331571BACKGROUND
  • Martin D. Postcodes and the 1991 census of population: issues, problems and prospects. Trans Inst Br Geogr. 1992;17(3):350-7.

    PMID: 12157823BACKGROUND
  • van Eerde MR, Kampinga HH, Szabo BG, Vujaskovic Z. Comparison of three rat strains for development of radiation-induced lung injury after hemithoracic irradiation. Radiother Oncol. 2001 Mar;58(3):313-6. doi: 10.1016/s0167-8140(00)00301-7.

    PMID: 11230893BACKGROUND

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: Over three weeks participants will be asked to record three consecutive days of dietary intake each week using a different tool. Participants will be assigned to an order they complete the three tools from six different sequence options. The order will be assigned based on auto number generation.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 8, 2025

First Posted

September 26, 2025

Study Start

September 1, 2025

Primary Completion

March 1, 2026

Study Completion

April 1, 2026

Last Updated

September 26, 2025

Record last verified: 2025-09

Locations